No abstract

Ocular toxicity of Anandron SIR, In studies previously published in 1983 and 1984 on treatment of prostate cancer with the combination of castration and Anandron'2two of the authors of the paper by Harnois et al. ' stressed the 'excellent tolerance and lack of secondary effects other than those related to hypoandrogenicity' of RU 23908 (Anandron). It is therefore surprising to read in 1986 an article by the same authors reporting a high incidence of adverse visual events, investigated in only 18 patients. No indication is given of how these 18 patients were selected among the 97 patients reported on in one of the above-mentioned articles.2 Three placebo-controlled studies of metastatic prostate cancer reported at the Second International Symposium on Cancer of the Prostate (Paris) in June 1986 did not confirm the results of Harnois et al. a much lower incidence of visual symptoms was noted (Table 1).

No abstract

No abstract